CareDx Stock News

CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Stree

Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter

The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positiv

The mean of analysts' price targets for CareDx (CDNA) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

CareDx, Inc (NASDAQ:CDNA ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, Managing Director Alex Johnson - President of Patient and

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street es

CareDx (CDNA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.13 per share a year ago.

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road

CareDx specializes in diagnostic testing for transplant patients. The company's revenue declined 3% year over year in the first quarter.

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-val

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healt

CareDx, Inc. (NASDAQ:CDNA ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Greg Chodaczek - IR Reginald Seeto - CEO Abhishek Jain - Interim CFO Conference Call Part